Genomic Vision Announces the Acceptance Notice of the Second Tranche of €1.0 Million Within the Framework of the Equity Fin...
July 04 2019 - 1:00PM
Business Wire
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a company
specialized in the development of in-vitro diagnostic (IVD) tests
for the early detection of cancers and genetic diseases and
applications for life sciences research (LSR), announces that it
has today initiated the process of issuing 10,000,000 new shares at
a unit price of €0.10, corresponding to a capital increase of €1.0
million, within the framework of the financing contract signed with
Winance in accordance with the approval granted by the Company’s
shareholders at the EGM of March 4, 2019.
Following this operation, the share capital of Genomic Vision
will consist of 33,474,390 shares. The new shares will be freely
tradable and immediately assimilated to the existing ordinary
shares listed on the Euronext market in Paris.
The main characteristics of this financing, comprising 4
tranches of shares with equity warrants attached (ABSAs) for a
total of €5 million, are described in the Prospectus granted visa
number 19-122 by the AMF French stock market authority on March 29,
2019 comprising a Note d’opération and a Document de référence
filed with the AMF under reference number R19-004.
***
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of
diagnostic solutions for the early detection of cancers and serious
genetic diseases and tools for life sciences research. Through the
DNA Molecular Combing, a strong proprietary technology allowing to
identify genetic abnormalities, GENOMIC VISION stimulates the
R&D productivity of the pharmaceutical companies, the leaders
of the diagnostic industry and the research labs. The Company
develops a robust portfolio of diagnostic tests (breast, ovarian
and colorectal cancers, myopathies) and analysis tools (DNA
replication, biomarkers discovery, gene editing quality control).
Based near Paris, in Bagneux, the Company has approximately 40
employees. GENOMIC VISION is a public listed company listed in
compartment C of Euronext’s regulated market in Paris (Euronext: GV
- ISIN: FR0011799907). For further information, please visit
www.genomicvision.com
ABOUT WINANCE
Winance is a global equity investor in SMEs that have a unique
competitive advantage and a capacity to deliver short and long-term
growth, in order to enable these companies to finance themselves
competitively for growth and/or working capital needs. Webiste:
www.winance.com
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the reference
document filed with the AMF under reference number R19-004 on March
29, 2019, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
Membre des indices CAC® Mid & Small et CAC®
All-Tradable
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190704005318/en/
Genomic Vision Aaron Bensimon Co-founder,
Chairman & CEO Tel.: +33 1 49 08 07 50
investisseurs@genomicvision.com
Ulysse Communication Press Relations
Bruno Arabian Tel.: +33 1 42 68 29 70
barabian@ulysse-communication.com
NewCap Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94
gv@newcap.eu
Genomic Vision (EU:GV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genomic Vision (EU:GV)
Historical Stock Chart
From Apr 2023 to Apr 2024